Author:
Stadlbauer Katharina,Stadlmayr Gerhard,Rüker Florian,Wozniak-Knopp Gordana
Abstract
AbstractNearly seventy years have passed since the first attempts to fuse the antibodies, „magic bullets“ with exquisite target specificity, into multispecific agents that can connect a targeted cell with an effector immune cell. Such efforts have triggered a plethora of engineering advancements to optimize the antigen engagement. Even the most conserved domains of the antibody molecule have been modified to achieve two unique chains pairing, or with an introduction of novel antigen binding sites.
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Biotechnology
Reference10 articles.
1. Skerra A, Pfitzinger I, Plückthun A (1991) The functional expression of antibody Fv fragments in Escherichia coli: improved vectors and a generally applicable purification technique. Biotechnology 9: 273–278
2. Ridgway JB, Presta LG, Carter P (1996) ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9: 617–621
3. Wozniak-Knopp G, Bartl S, Bauer A et al. (2010) Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 23: 289–297
4. Maruhashi T, Sugiura D, Okazaki IM et al. (2020) LAG-3: from molecular functions to clinical applications. J Immunother Cancer 8: e001014
5. Kraman M, Faroudi M, Allen NL et al. (2020) FS118, a bispecific antibody targeting LAG-3 and PD-L1, enhances T-cell activation resulting in potent antitumor activity. Clin Cancer Res 26: 3333–3344